Opus Genetics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
IRD$4.20+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share amounts and par value)
| As of December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $45,091 | $30,321 |
| Accounts receivable | 1,995 | 3,563 |
| Contract assets and unbilled receivables (Note 10) | 1,170 | 2,209 |
| Prepaids and other current assets | 1,788 | 515 |
| Short-term investments | — | 2 |
| Total current assets | 50,044 | 36,610 |
| Property and equipment, net | 199 | 252 |
| Total assets | $50,243 | $36,862 |
| Liabilities, Series A preferred stock and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $3,293 | $3,148 |
| Accrued expenses and other liabilities | 4,488 | 8,147 |
| Total current liabilities | 7,781 | 11,295 |
| Warrant liabilities | 25,985 | — |
| Funding agreement, related party | 1,129 | — |
| Total liabilities | 34,895 | 11,295 |
| Commitments and contingencies (Note 3 and Note 9) | ||
| Series A preferred stock, par value $0.0001; no shares and 14,146 shares were designated as of December 31, 2025 and 2024, respectively; no shares and 14,145.374 shares issued and outstanding at December 31, 2025 and 2024, respectively. | — | 18,843 |
| Stockholders’ equity: | ||
| Preferred stock, par value $0.0001; 10,000,000 and 9,985,854 shares authorized as of December 31, 2025 and 2024, respectively; no shares issued and outstanding at December 31, 2025 and 2024. | — | — |
| Common stock, par value $0.0001; 125,000,000 authorized as of December 31, 2025 and 2024; 69,894,507 and 31,574,657 shares issued and outstanding at December 31, 2025 and 2024, respectively. | 7 | 3 |
| Additional paid-in capital | 203,930 | 145,719 |
| Accumulated deficit | (188,589) | (138,998) |
| Total stockholders’ equity | 15,348 | 6,724 |
| Total liabilities, Series A preferred stock, and stockholders’ equity | $50,243 | $36,862 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.